17 March 2023 false No description of principal activity Taxfiler 2024.6 14737098business:PrivateLimitedCompanyLtd2023-03-172024-03-31 147370982023-03-16 147370982023-03-172024-03-31 14737098business:AuditExemptWithAccountantsReport2023-03-172024-03-31 14737098business:FilletedAccounts2023-03-172024-03-31 147370982024-03-31 14737098business:Director12023-03-172024-03-31 14737098business:Director22023-03-172024-03-31 14737098business:RegisteredOffice2023-03-172024-03-31 14737098core:WithinOneYear2024-03-31 14737098core:ShareCapitalcore:PreviouslyStatedAmount2024-03-31 14737098core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-03-31 14737098core:PreviouslyStatedAmount2024-03-31 14737098business:SmallEntities2023-03-172024-03-31 14737098countries:EnglandWales2023-03-172024-03-31 14737098core:FurnitureFittings2023-03-172024-03-31 14737098core:ComputerEquipment2023-03-172024-03-31 14737098core:FurnitureFittings2023-03-16 14737098core:ComputerEquipment2023-03-16 14737098core:FurnitureFittings2024-03-31 14737098core:ComputerEquipment2024-03-31 iso4217:GBP xbrli:pure
Company Registration No. 14737098 (England and Wales)
Veripharm Ltd Unaudited accounts for the period from 17 March 2023 to 31 March 2024
Veripharm Ltd Unaudited accounts Contents
Page
- 2 -
Veripharm Ltd Company Information for the period from 17 March 2023 to 31 March 2024
Directors
S P Church G E Church
Company Number
14737098 (England and Wales)
Registered Office
123 Cross Lane East Gravesend Kent DA12 5HA
Accountants
King & Taylor 123 Cross Lane East Gravesend Kent DA12 5HA
- 3 -
Veripharm Ltd Statement of financial position as at 31 March 2024
2024 
Notes
£ 
Fixed assets
Tangible assets
277 
Current assets
Debtors
5,628 
Cash at bank and in hand
41,203 
46,831 
Creditors: amounts falling due within one year
(33,792)
Net current assets
13,039 
Net assets
13,316 
Capital and reserves
Called up share capital
2 
Profit and loss account
13,314 
Shareholders' funds
13,316 
For the period ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 20 November 2024 and were signed on its behalf by
S P Church Director Company Registration No. 14737098
- 4 -
Veripharm Ltd Notes to the Accounts for the period from 17 March 2023 to 31 March 2024
1
Statutory information
Veripharm Ltd is a private company, limited by shares, registered in England and Wales, registration number 14737098. The registered office is 123 Cross Lane East, Gravesend, Kent, DA12 5HA.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
5 year straight line
Computer equipment
5 year straight line
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
4
Tangible fixed assets
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 17 March 2023
- 
- 
- 
Additions
170 
176 
346 
At 31 March 2024
170 
176 
346 
Depreciation
Charge for the period
34 
35 
69 
At 31 March 2024
34 
35 
69 
Net book value
At 31 March 2024
136 
141 
277 
- 5 -
Veripharm Ltd Notes to the Accounts for the period from 17 March 2023 to 31 March 2024
5
Debtors
2024 
£ 
Amounts falling due within one year
Trade debtors
5,628 
6
Creditors: amounts falling due within one year
2024 
£ 
Taxes and social security
7,750 
Loans from directors
25,202 
Accruals
840 
33,792 
7
Average number of employees
During the period the average number of employees was 1.
- 6 -